Concepedia

Thomas Hawthorne

TH

Statistics

Publications

38

Citations

3.1K

H-Index

25

Active since

1994

Affiliations

Celldex Therapeutics (United States)(Current)

Dana-Farber Cancer Institute

Sarah Cannon

Cornell University

Providence Portland Medical Center

Thomas Hawthorne is an author at Celldex Therapeutics (United States) specializing in medicine, oncology, and pharmacology.

Publications per year

1994–2025

38

Publications

38

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117

Marina Caskey, Florian Klein, Julio C. C. Lorenzi et al. · Nature · 2015 · 774 citations

, , +12

HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

Johannes F. Scheid, Joshua A. Horwitz, Yotam Bar‐On et al. · Nature · 2016 · 482 citations

, , +16

EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer

Denise A. Yardley, Robert Weaver, Michelle Melisko et al. · Journal of Clinical Oncology · 2015 · 189 citations · Full text

, , +17

Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors

Howard A. Burris, Jeffrey R. Infante, Stephen M. Ansell et al. · Journal of Clinical Oncology · 2017 · 132 citations

, , +17

Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets

Nina Bhardwaj, Philip Friedlander, Anna C. Pavlick et al. · Nature Cancer · 2020 · 126 citations

, , +15

1–5 of 38